Rachel H. Rose

Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability

Manoranjenni Chetty, Rachel H. Rose, Khaled Abduljalil et al. · Frontiers in Pharmacology · 2014 · 58 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A novel fluorescent histamine H₁ receptor antagonist demonstrates the advantage of using fluorescence correlation spectroscopy to study the binding of lipophilic ligands

Rachel H. Rose, Stephen J. Briddon, Stephen J. Hill · British Journal of Pharmacology · 2012 · 52 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Incorporating Target Shedding Into a Minimal PBPK–TMDD Model for Monoclonal Antibodies

L Li, I. Gardner, Rachel H. Rose et al. · CPT Pharmacometrics & Systems Pharmacology · 2014 · 39 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model

Manoranjenni Chetty, Linzhong Li, Rachel H. Rose et al. · Frontiers in Immunology · 2015 · 35 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs

Rachel H. Rose, David B. Turner, Sibylle Neuhoff et al. · The AAPS Journal · 2017 · 28 citations

Pharmacy, Pharmacokinetics, Pharmacology +16